scholarly journals The hemostatic parameters in pregnant women with different types of diabetes mellitus

2021 ◽  
Vol 24 (3) ◽  
pp. 251-261
Author(s):  
R. V. Kapustin ◽  
E. V. Kopteeva ◽  
O. N. Arzhanova ◽  
A. V. Tiselko ◽  
N. Е. Androsova ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Pregnant Women ◽  
Von Willebrand Factor ◽  
Antithrombin Iii ◽  
Correction Method ◽  
Diabetic Pregnancy ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
D Dimer ◽  
In Pregnancy

BACKGROUND: The prevalence of diabetes mellitus (DM) in pregnancy is on the rise. Despite that gestational hypercoagulability is a physiological condition, diabetic pregnancy is associated with a high risk of venous thromboembolic complications (VTEC). There are many surveys related to the hemostatic parameters in non-pregnant women, but studies in pregnant women are not enough.AIMS: To assess the coagulation and vascular-platelet hemostasis parameters in pregnant women with various types of diabetes mellitus, taking into account its correction method. The data were compared with these indicators in women with preeclampsia and healthy pregnant women at the same gestational age.MATERIALS AND METHODS: An observational, single-center, retrospective cohort study was carried out at D.O. Ott ­Research Institute of Obstetrics, Gynecology, and Reproductive Medicine. The study included 1994 pregnant women who presented several groups taking into account the type of DM and its correction method, a group of women with preeclampsia (PE), and healthy women. The analysis of clinical data was carried out at 28–32 gestational weeks from 2012 to 2017. The study’s primary endpoint was taken as indicators of fibrinogen content, prothrombin index, thrombin time, activated partial thromboplastin time (APTT), and international normalized ratio (INR) antithrombin III, D-dimer, von Willebrand factor, and fibronectin. Additionally, the incidence of VTEC during pregnancy and within six weeks after delivery, gestational arterial hypertension, preeclampsia, fetal growth restriction, premature birth, and stillbirth cases was assessed.RESULTS: in pregnant women with various types of diabetes mellitus and preeclampsia, a state of pathological hypercoagulation was observed compared to the control group. These changes were characterized by an increase and activation of the following blood parameters: fibrinogen, the degree and rate of platelet aggregation, D-dimer, homocysteine, von Willebrand factor, and fibronectin. At the same time, the content of antithrombin III was significantly reduced in patients with DM. Correlation analysis established a direct relationship between the range of the studied factors with the degree of glycemic control and the frequency of obstetric complications.CONCLUSIONS: Diabetes mellitus in pregnancy is associated with a hypercoagulation condition and overexpression in the synthesis of endothelial dysfunction markers. Moreover, the severity of these processes depends on the type of DM and the severity of metabolic disorders. In diabetic pregnancy, exceptional attention to coagulation indicators, regular monitoring, and preventive treatment is required in order to improve the perinatal outcomes.

The Association between Fibrinogen, von Willebrand Factor, Antithrombin III, and D-dimer Levels and Survival Outcome by 36 Months from Ovarian Cancer

2006 ◽  
Vol 12 (1) ◽  
pp. 3-8 ◽  
Author(s):  
Stephen C. L. Koh ◽  
R. Khalil ◽  
F -K Lim ◽  
A. Ilancheran ◽  
M. Choolani
Keyword(s):  
Ovarian Cancer ◽  
Von Willebrand Factor ◽  
Antithrombin Iii ◽  
Survival Outcome ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
D Dimer

scholarly journals Von Willebrand Factor, ADAMTS13 and D-Dimer Are Correlated with Different Levels of Nephropathy in Type 1 Diabetes Mellitus

PLoS ONE ◽  
2015 ◽  
Vol 10 (7) ◽  
pp. e0132784 ◽  
Author(s):  
Caroline Pereira Domingueti ◽  
Luci Maria S. Dusse ◽  
Rodrigo Bastos Fóscolo ◽  
Janice Sepúlveda Reis ◽  
Joyce Maria Annichino-Bizzacchi ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Von Willebrand Factor ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Different Levels ◽  
D Dimer

scholarly journals Vascular factor dynamics in therapy for microangiopathy with underlying type 1 diabetes mellitus

2020 ◽  
Vol 27 (6) ◽  
pp. 60-70
Author(s):  
E. S. Krutikov ◽  
V. A. Zhitova
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Endothelial Dysfunction ◽  
Von Willebrand Factor ◽  
Protein C ◽  
Antithrombin Iii ◽  
Endothelial Cell Count ◽  
Von Willebrand ◽  
Willebrand Factor

Background. The adverse impact of chronic hyperglycaemia on vascular wall in diabetes mellitus includes endothelial dysfunction with subsequent development of diabetic microangiopathy. Microangiopathy can be corrected via adequate glycaemic control for establishing a target level of glycated haemoglobin. Considering a multiplex nature of metabolic and vascular regulation, a comprehensive approach is required for simultaneous correction of rheological disorders, hypercoagulation and endothelial dysfunction.Objectives. Estimation of vascular factors (von Willebrand factor, desquamated endothelium, antithrombin III, protein C, VEGF) and capillaroscopic patterns in therapy for type 1 diabetes with methylethylpyridinol in comparison with sulodexide.Methods. A total of 89 patients with type 1 diabetes were examined and separated by two cohorts: 42 patients receiving sulodexide (cohort 1) and 47 patients receiving methylethylpyridinol (cohort 2). Therapy duration was 14 days. Both cohorts were estimated pre- and post-treatment endothelial conditions (activity of von Willebrand factor, VEGF, desquamated endothelial cell count), anticoagulant indicators (activity of antithrombin III, protein C) and had capillaroscopy with functional test and oximetry.Results. Diabetes patients in pre-treatment exhibited signs of endothelial dysfunction, reduced blood anticoagulant protection and capillary constriction. Both cohorts in post-treatment showed the significantly reduced von Willebrand factor, VEGF activity and desquamated endothelial cell count. The anticoagulant system revealed positive dynamics; capillaroscopy reported limiting of the capillary transition zonal diameter and a certain improvement in functional performance.Conclusion. Patients with type 1 diabetes were revealed with endothelial dysfunction and an increased blood procoagulant activity. Both sulodexide and methylethylpyridinol treatments improved endothelial dysfunction and anticoagulant blood protection. Both preparations can be used for complex microangiopathy correction in patients with <10-years history of type 1 diabetes mellitus.

scholarly journals Design of the Von Willebrand Factor in Pregnancy (VIP) Study

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 29-29
Author(s):  
Jill M Johnsen ◽  
Sarah Ruuska ◽  
Peter A. Kouides ◽  
Barbara A. Konkle
Keyword(s):  
Pregnant Women ◽  
Von Willebrand Factor ◽  
Postpartum Period ◽  
Research Funding ◽  
The United States ◽  
Activity Levels ◽  
Laboratory Results ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
In Pregnancy

Background: von Willebrand factor (VWF) and factor VIII (FVIII) levels rise during healthy pregnancy by approximately 200 - 250%. VWF increases are markedly less pronounced or absent in pregnant women with von Willebrand disease (VWD). Women with VWD have relatively high rates of postpartum hemorrhage (PPH), even with VWD-specific treatment. Current guidance provides general recommendations for bleeding prophylaxis for childbirth for women with VWD. However, this guidance has been largely based on non-pregnant treatments and does not specify target VWF levels or duration of VWF replacement or antifibrinolytic treatment, particularly for women whose VWF levels do not reach 50-100% by the third trimester. There is also conflicting evidence about which laboratory assays are associated with increased PPH in VWD. Study Design: The Von Willebrand Factor in Pregnancy (VIP) Study (NCT04146376) is an investigator-initiated prospective, open-label, multi-center cohort study in the United States that aims to document the rate of PPH in women with VWD and to determine the effectiveness of maintaining VWF activity levels are over 100% at the time of delivery and the immediate postpartum period. Eligibility and Enrollment: Pregnant women ≥18 years and diagnosed with VWD (Type 1 with ≤ 30% VWF levels, Type 2, or Type 3) are eligible for enrollment. VWF genotyping will be performed as part of the study; patients can opt to receive these genetic results clinically. Exclusion criteria include other coagulopathies or clinical suspicion of preeclampsia, eclampsia, or HELLP (Hemolysis, Elevated Liver enzyme levels, and Low Platelet levels) syndrome. Consecutive enrollment will continue until 65 Non-Corrector patients and a maximum of 30 Corrector patients have completed the study. Corrector and Non-Corrector group determination: All subjects will have VWF levels drawn between weeks 34 and 38 of pregnancy including VWF antigen, VWF activity (e.g. VWF:RCo, VWF:GPIbM), and FVIII activity. The 34 - 38 week laboratory results will be used to determine if patients are in the "Non-Corrector" group, defined by one or more laboratory values still measuring &lt; 100%, or in the "Corrector" group, defined by having all levels rise to over 100% by this time in pregnancy. Treatment and assessments of bleeding and VWF levels during childbirth and the postpartum period: Non-Correctors will receive VWF replacement with wilate® to achieve VWF activity levels of 100-150% during delivery and immediate 72 hour postpartum period, followed by VWF levels of 50-100% for 5-10 days after delivery, depending on the mode of delivery. Patients in both the Corrector and Non-Corrector groups will receive tranexamic acid beginning immediately after delivery until postpartum day 14. Outcomes. The primary outcome measure will be the rate of PPH within the first 24 hours postpartum. Other outcome measures will include the rate of secondary PPH (from 24 hours to 6 weeks postpartum) using the Pictoral Bleeding Assesment Chart (PBAC) and other clinical and laboratory indicators of excessive bleeding; analysis of laboratory coagulation assays using a central laboratory for analysis relative to clinical outcomes and local laboratory results; and occurrence of adverse events including thrombosis. Summary. The VIP study should provide a better understanding of bleeding due to childbirth in women with VWD relative to VWD diagnosis, VWF levels, and other laboratory assessments of VWF-associated parameters. These data will also provide information important to developing evidence-based management of these patients. Disclosures Johnsen: Octapharma: Research Funding. Konkle:Uniquire: Research Funding; Takeda: Research Funding; CSL Behring: Consultancy; BioMarin: Consultancy; Pfizer: Consultancy, Research Funding; Sanofi: Consultancy, Research Funding; Roche: Consultancy; Baxalta: Research Funding; Spark: Consultancy, Research Funding; Sigilon: Consultancy, Research Funding.

Association between Von Willebrand factor, disintegrin and metalloproteinase with thrombospondin type 1 motif member 13, d -Dimer and cystatin C levels with retinopathy in type 1 diabetes mellitus

2016 ◽  
Vol 459 ◽  
pp. 1-4 ◽  
Author(s):  
Caroline Pereira Domingueti ◽  
Jéssica A. Fuzatto ◽  
Rodrigo B. Fóscolo ◽  
Janice S. Reis ◽  
Luci M. Dusse ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Cystatin C ◽  
Von Willebrand Factor ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
D Dimer

Endothelial dysfunction in hypertension in pregnancy: associations between circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factor

2011 ◽  
Vol 100 (6) ◽  
pp. 531-537 ◽  
Author(s):  
V. J. Karthikeyan ◽  
Andrew D. Blann ◽  
Sabah Baghdadi ◽  
Deirdre A. Lane ◽  
D. Gareth Beevers ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Endothelial Dysfunction ◽  
Progenitor Cells ◽  
Von Willebrand Factor ◽  
Circulating Endothelial Cells ◽  
Hypertension In Pregnancy ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
In Pregnancy

Mo-P2:193 Validity of plasma fibrinogen, D-dimer and Von Willebrand factor as markers of cardiovascular morbidity in patients on chronic haemodialysis

2006 ◽  
Vol 7 (3) ◽  
pp. 89 ◽  
Author(s):  
D. Kirmizis ◽  
A. Tsiandoulas ◽  
M. Pangalou ◽  
E. Koutoupa ◽  
P. Rozi ◽  
...  
Keyword(s):  
Von Willebrand Factor ◽  
Cardiovascular Morbidity ◽  
Plasma Fibrinogen ◽  
Chronic Haemodialysis ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
D Dimer
Sign in / Sign up

Export Citation Format

Share Document